Kornimate/medical-research-clean huggingface dataset:
clinical evaluation of a universal adhesive in noncarious cervical lesions

Conditions: Cervical Lesions

Summary: the purpose of this prospective clinical trial will be to evaluate the efficacy of an fda approved and marketed universal dental adhesive formulation in adult noncarious cervical lesions using self-etch and selective etch approaches. the hypothesis is that using a selective enamel etch with this universal adhesive will enhance the restoration margin performance.

the purpose of this prospective clinical trial will be to evaluate the efficacy of a newly formulated universal dental adhesive formulation in adult noncarious cervical lesions using self-etch and selective etch approaches. thirty-three patients with at least two non-carious cervical lesions will receive one restoration utilizing the self-etch universal adhesive with no separate enamel etching and another restoration utilizing the universal adhesive and a a selective etch protocol in which in which enamel is etched with 37% phosphoric acid. after a screening/baseline visit at which the restorative procedures listed above will conducted, the patient will be seen at recall visits after approximately 6, 12 and 24 months to observe sensitivity, retention, marginal discoloration and marginal adaptation.

Eligibility criteria:
inclusion criteria: * 1.1. inclusion criteria 1. willing to provide written consent and authorization for participation. 2. be between 20 and 75 years of age at the time of recruitment 3. have at least two non-carious cervical lesions present in canine or premolar teeth; 4. anticipates availability for recalls (roughly 6 month, 12 month, and 24 month) through the two-year study period 5. the lesions selected will be at least 1 mm in depth (measured with a perio probe) and contain both enamel and dentin margins. exclusion criteria: 1.2. exclusion criteria 1. severe medical complications (organ transplants, cancer, immunocompromised, long term antibiotic or steroid therapy); 2. active caries on study teeth; 3. bleeding on probing of study teeth; 4. generalized severe periodontitis; 5. patient reported symptoms (burning mouth, loss or diminished taste, saliva amount too little, needs liquids to eat dry foods) or clinical signs (erythematous tongue, chelitis, lack of pooled saliva) associated with dry mouth; 6. patients determined to be at a high risk of caries as determined by a caries risk assessment

Keywords: noncarious cervical lesions dental adhesive retention enamel margin discoloration self etch selective etch procedures
a clinical study on the combined magnetic and oxygen treatment for bell's palsy

Conditions: Bell's Palsy

Summary: the aim of this clinic trial is to testify the efficacy of using new and noninvasive therapy, called simultaneous "magnetic and oxygen treatment along meridians and collaterals" (momc), to treat bell's palsy.

between june 1998 and january 2005, a total of 3002 subjects with bp were evaluated, 882 patients fulfilled the inclusion criteria and entered the study. patients were randomly assigned to either the prednisone-valacyclovir group(group 1) or the magnetic-oxygen group(group 2) . among the 882 patients completing the study,825 patients in group 1 received prednisone, given as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days. 57 patients in group 2 received magnetic-oxygen treatment:momc treatment was given as daily 20 min section for 10 days with 2\~3 days of intermission between;oxygen therapy was given simultaneously at a flow rate of 2\~3.0 l / min for the same duration during all acupuncture sections. clinical evaluation for the severity of paralysis was performed immediately before and after the treatment using the facial nerve grading (fng) scores of house and brackmann system.

Eligibility criteria:
inclusion criteria: 1. only patients with complete (or nearly complete) non-recurrent facial paralysis (grade 5-6/6) for more than 1 months 2. the first time to onset the disease 3. on one side of the face paralysis 4. willing to finish the whole observation period 5. with written consent form signed by themselves. exclusion criteria: 1. facial palsy caused by other disease, such as infectivity multiple radiculitis, tumor which offend temporal bone, cerebral trauma 2. facial palsy combine diabetes, the severe disease of heart vessel, cerebral vessel, liver, kidney, lung, and psychosis 3. patient with hunt's syndrome 4. pregnant women or women in lactation 5. patients are participating other clinical research

Keywords: magnetic oxygen bell's palsy acupuncture
short-term fasting as an enhancer of chemotherapy: pilot clinical study on colorectal carcinoma patients

Conditions: Fasting

Summary: this study will evaluate the ability of short-term fasting to reduce chemotherapy toxicity and enhance anti-tumour response in patients with colorectal carcinoma subjected to chemotherapy.

fasting for 24-48 hours during chemotherapy improves the response of the immune system against tumors and reduces chemotherapy toxicity through yet unknown mechanisms. the investigators have found that fasting induces the activation of p21, a protein that stops cell proliferation and plays important immune roles. the investigators hypothesize that p21 induction with short-term fasting enhances the immune anti-tumour response and reduces chemotherapy toxicity. to test this, half of the colorectal carcinoma (crc) participants will follow 48 hours of fasting, 24 before and 24 after chemotherapy, under constant and specialized nutritional supervision. while the other half will follow a standard diet. a complete blood immunological profile at each chemotherapy cycle will be generated in collaboration with expert cytometrists, and gene expression, biochemical parameters, tumor evolution and toxicity markers will be measured. the investigators will (1) perform a complete analysis of immune cells to characterize the immune effects of fasting during chemotherapy; (2) analyze the effects of fasting on genes, metabolites and other molecules, to identify the responsible biological mechanisms, focusing on p21; (3) assess the reduction of chemotherapy toxicity in patients of colorectal carcinoma subjected to short-term fasting during chemotherapy. our project will further explore a safe, inexpensive, relatively unexplored and powerful nutritional intervention that can improve the quality of life and survival rates of millions of cancer patients: short-term fasting. also, our project will have an important scientific impact, since previous reports have not yet described a clear mechanism explaining the beneficial effects of short-term fasting with chemotherapy

Eligibility criteria:
inclusion criteria: * participants with malignant colorectal neoplasia * good metabolic state (bmi\>22) * good nutritional tests * normal haematological and biochemical parameters * normal renal and hepatic function * no loss of weight during the chemotherapy treatment exclusion criteria: * bmi\<22 * pregnancy or lactating women * bad nutritional state * 3% weigh loss during the last month or more than 5% in the last three months * diagnosis of type 2 diabetes mellitus or hypertension * diagnosed hepatic, renal or cardiovascular disease * respiratory of psychiatric disease * nausea or vomiting, gastrointestinal disease

Keywords: short-term fasting colorectal cancer chemotherapy toxicity immune response
phase ii study of combined chemotherapy with arsenic trioxide in stage 4/m neuroblastoma

Conditions: Neuroblastoma

Summary: this clinical trial aims to explore and evaluate the efficacy and safety of combined chemotherapy with arsenic trioxide for stage 4/m neuroblastoma.

this study is a prospective, single-arm, open-lable, multi-center clinical trial. children≤ 14 years old are eligible for this study if they were newly diagnosed with neuroblastoma and assessed as stage 4 according to the international neuroblastoma staging system (inss) or stage m according to the international neuroblastoma risk group (inrg) respectively. patients enrolled in this study will receive combined induction chemotherapy with arsenic trioxide following an modifed protocol based on n7 and nb2004 protocols. objective response rate (orr) at 4 weeks after completing induction chemotherapy was defined as the main outcome and adverse events were monitored and graded in the meantime.

Eligibility criteria:
inclusion criteria: 1. untreated stage 4/m neuroblastoma patients according to the international neuroblastoma staging system（inss) or the international neuroblastoma risk group (inrg) staging system; 2. patients not more than 14 years old; 3. there are measurable lesions; 4. guardians agreed and signed informed consent. exclusion criteria: 1. patients who had suffered from other tumors and received chemotherapy or abdominal radiotherapy. 2. patients with one or more critical organs failure such as heart, brain, kidney failure.

Keywords: neuroblastoma arsenic trioxide children
exploring emotional intelligence and cognitive flexibility in anorexia nervosa and parkinson's disease.

Conditions: Anorexia Nervosa; Parkinson Disease

Summary: the main aim of this study is to demonstrate how disorders characterized by different types of "inflexibility", cognitive-affective type for anorexia nervosa and motor one for parkinson's disease, have an impact on how emotional stimuli are processed and on the transition within emotional states.

although many psychometric models have been developed on emotions, affect measurements, which represent the measurement of behavioural, subjective and neuropsychophysiological changes associated with an emotional episode, still remains one of the most debated topics. emotions are entities with blurred boundaries and with substantial idiosyncrasies that characterize their measurable manifestations. one of the most consolidated theoretical reference models for measuring affect is that of james russel called the "affective core model". according to this model, emotion arises when the undifferentiated and pre-reflective magma of affect (core affect) is attracted by an external (or internal) object that can be defined as emotigenic, i.e. capable of defining the nature of emotional experience by orienting it along two dimensions principal factors. the most used theoretical model for affect measurement is the one that describes an emotional episode in the light of two distinguishable continuous dimensions: that of hedonic value (identifies the degree of pleasantness of the emotional event), of a subjective nature, and that of arousal or psychophysiological activation. although this model has been widely corroborated in various disciplines, there is still a lack of a clear description of the process that allows an individual to transition from one emotionally object-oriented state to another. this project proposes and intends to validate a new modality of three-dimensional psychometric modeling of emotions, based on the intersection between the consolidated two-dimensional model of arousal-valence and a third purely cognitive component definable as mental flexibility, capable of including high-level cognitive processes, intrinsically connected with the emotional sphere, such as emotional intelligence (emotional intelligence, ei) and emotional regulation.

Eligibility criteria:
inclusion criteria: * parkinson's disease * anorexia nervosa * written informed consent exclusion criteria: * other psychiatric disorders * acute infectious diseases * chronic inflammatory diseases * other disorders of central nervous system * pregnancy or breastfeeding * tachy or bradyarrhythmias, other cardiac rhythm alterations that compromise the study of heart rate variability

Keywords: emotional intelligence cognition emotional valence anorexia nervosa parkinson's disease
quantitative evaluation of osteopathic treatment in temporomandibular joint disorders using magnetic resonance imaging

Conditions: Temporomandibular Disorders, Articular Disc Disorder (Reducing or Non-Reducing); Osteopathy in Temporomandibular Disorders

Summary: the aim of this study is to assess the impact of osteopathic manual treatment in patients with an anterior disc displacement over sleep and health quality, pain scores and the movement of the condyle and disc of the temporomandibular joint (tmj) quantitatively.

patients with tmd will involve to this study. after having the diagnose in yeditepe u. dental hospital patients will be sent to the radiology department. mri images will be gathered in sagittal, coronal and axial plane for each patient before and after treatment. volunteers will be divided into two groups; (1) splint therapy for 6 weeks, (2) splint therapy + osteopathy 2 times a week for 6 weeks randomly. at the end of the treatment, patients will be sent to radiology for the second images. health survey and pain scores, disc condyle angle, disc and condyle displacements will be measured and compared inter and intra groups.

Eligibility criteria:
inclusion criteria: • clinical diagnosis of tmd (anterior disc displacement) exclusion criteria: * active orthodontic treatment * systemic diseases * oral or dental pathologies * dental implant placement * exodontia within 6 months * cranial and cervical trauma or surgery * taking antidepressant medication * contraindication of mri scans

Keywords: temporomandibular disorders, anterior disc displacement with reduction, mri analyses, osteopathy
hydrochlorothiazide to protect polycystic kidney disease patients and improve their quality of life

Conditions: ADPKD

Summary: autosomal dominant polycystic kidney disease (adpkd) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function. tolvaptan (a v2r antagonist) is currently the only effective treatment for preserving renal function in adpkd. however, side-effects such as polyuria limit its tolerability and thereby the therapeutic potential. this study will test whether co-administration with hydochlorothiazide can improve v2ra efficacy (slowing kidney function decline) and tolerability (quality of life) in adpkd. approximately 300 patients will be enrolled.

aims: the main objectives of the current study are to prospectively test whether hct co-treatment can improve v2ra efficacy (slowing kidney function decline) and tolerability (quality of life) in pkd. study design: investigator driven randomized placebo-controlled multicenter trial study population: 300 adpkd patients of ≥18 years, with an egfr of \> 25 ml/min/1.73m2, on stable treatment with the highest tolerated dose of v2ra intervention: oral hct 25 mg once daily or matching placebo for a total of 156 weeks. the randomization ratio will be 1:1. study visit schedule: study measurements will be performed during 12-weekly visits (which is routine care for v2ra treated patients), except for one additional study visit (or telephone call) 2 weeks after the start of treatment primary study outcome: slope of kidney function decline (measured by egfr)

Eligibility criteria:
inclusion criteria: * adpkd diagnosis (modified ravine criteria) * ≥18 years old * egfr \> 25 ml/min/1.73m2 * on stable treatment with the highest tolerated dose of v2ra for a minimum of 3 months exclusion criteria: * known intolerance to hydrochlorothiazide * use of any diuretic * orthostatic hypotension complaints or blood pressure \<105/65mmhg during screening visit * uncontrolled hypertension (blood pressure \>160/100mmhg) * hypokalemia (\<3.5 mmol/l) * history of active gout on maintenance preventive treatment for gout (allopurinol, desuric and/or colchicine), defined as ≥2 episodes during the last year * history of skin cancer (basal cell, squamous cell and melanoma)

Keywords: adpkd tolvaptan hydrochlorothiazide quality of life side effects polyuria
changes in microbiota and iron status after iron fortification of complementary foods

Conditions: Bacterial Infections

Summary: infants and children under two years are the group with the highest rates of iron deficiency anemia. provision of sufficient dietary iron to this age group is a challenge, and in-home iron fortification of complementary foods using micronutrient powders can be an effective approach. however, who has recently cautioned against untargeted use of in-home micronutrient powders that contain the entire iron rda for a child in a single dose in areas with high rates of infections from malaria and diarrheal disease. therefore, in this study, we will investigate the effect on the infant gut microbiota of a low dose (ca. 25% of the rda) of highly bioavailable iron, provided by a micronutrient powder added to a complementary food. the study aim is to determine if in-home fortification using an iron-containing micronutrient powder in kenyan infants will improve iron status and/or modify the composition and metabolic activity of the gut microbiota. active surveillance will be done weekly to monitor the health of the infants. our study will be done in a subgroup (n=160) of a larger double-blind controlled feeding trial in which 330 infants will be randomized to receive a micronutrient powder containing either 2.5 mg iron or no iron for 1 year. in our substudy, the infants will be studied only over the first 6 months of the 1 year intervention. blood samples, taken at baseline and after 6 months will be used to define the iron status and the anemia level of the infants. stool samples (2 at baseline before intervention, 6 throughout the study and additional samples in case of diarrhea) will be obtained for analysis of the gut microbiota. in the entire study (n=330), we will measure changes in iron status over 1 year.


Eligibility criteria:
inclusion criteria: * mother at least ≥15 years of age, infants 5.5- 6.5 months * willingness to provide informed consent * apparent good health * long-term residence in study site and anticipating residing in the area for at least 3 years * speak a mjikenda language or kiswahili in the home * willingness to provide blood samples during clinic visits exclusion criteria: * hemoglobin \<70 g/l for infants; these infants will be referred for treatment at the local health clinic/hospital. * acute or chronic pulmonary, cardiovascular, hepatic, renal or neurological condition or any other finding that in the opinion of the pi or co-researchers that would increase risk of participating in the study. * other conditions that in the opinion of the pi or co-researchers would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol
biomarker for rapid diagnosis of hemispheric stroke

Conditions: Acute Stroke

Summary: the aim of the study is to estimate the diagnostic accuracy of a combined biomarker test (including nmda-receptor fragments \[nr2-peptide\] and glial fibrillary acidic protein) used to differentiate between cerebral ischemia and intracerebral hemorrhage in patients with acute hemispheric stroke.


Eligibility criteria:
inclusion criteria: * hemiparesis * at least one sign of cortical involvement (e.g., aphasia, neglect, gaze deviation, reduced level of consciousness) * hospital admission within 4.5 hours after symptom onset exclusion criteria: * stroke/tia within the last 3 months * traumatic brain injury within the last 3 months * history of brain tumor
longitudinal follow-up study for food allergies

Conditions: Food Allergy

Summary: the purpose of this study is to evaluate the clinical usefulness of assessing specific human allergy antibodies and other immunologic parameters associated with the diagnosis, evolution, and management of allergic disease.

the purpose of this study is to strengthen our ability to understand the long-term effects of food immunotherapy on the immune system and how it may induce tolerance to foods that participants were once allergic to. investigators hope to determine tools and immunologic parameters that can help predict sustained desensitization and tolerance to food allergens following food immunotherapy. by evaluating the in-depth characteristics of allergy antibody populations and other immunologic parameters and comparing them to clinical disease, the investigators may uncover a more sound way to diagnose, follow and treat food allergic disease over time. investigators will follow up with participants who underwent immunotherapy to food allergens as volunteers in clinical trials at the sean n. parker center and assess whether they experience sustained desensitization to these foods in the long-term. investigators will investigate the properties of the participants' immune cells and how they are affected over time by the ingestion of these food allergens. investigators will follow the significance of different dosing regimens in terms of achieving tolerance. differences in immune cell characteristics and other biological parameters may help predict the nature of a participant's tolerance to the food allergens and may help in the development of tools to determine permanent tolerance.

Eligibility criteria:
inclusion criteria: * patients ages 6 months through 70 years who have previously undergone a food immunotherapy protocol only at our center. exclusion criteria: * none. however, if a participant becomes pregnant, their clinic visit may be postponed until after delivery and/or lactation period. these subject can postpone visits for one year and choose to skip visits during pregnancy and another year after (if breastfeeding).

Keywords: ige allergy tolerance immunotherapy desensitization
the influence of aerobic exercise on cognitive functioning in schizophrenia.

Conditions: Schizophrenia

Summary: the aim of this study is to look at the effects of aerobic exercise (ae) on daily and neurocognitive functioning including memory, attention, the ability to plan activities, and learn new information. participants will be assigned by chance to receive regular care or exercise sessions in addition to regular care. this study will allow determining the potential positive influence of ae on cognitive and daily functioning in individuals with schizophrenia.

individuals with schizophrenia often display cognitive difficulties. studies among non-clinical populations suggest that aerobic exercise (ae) training is effective in increasing both aerobic fitness and cognitive functioning. however, these associations have not been studied among individuals with schizophrenia, despite the presence of highly sedentary lifestyle in this population to elucidate this putative link, the present study will evaluate the influence of ae on cognitive functioning and daily functioning in individuals with schizophrenia using a single-blind, randomized clinical trial. outpatient individuals with schizophrenia receiving treatment will be randomly assigned to ae training or treatment as usual (tau). participants in the ae training will undergo a 12-week, 3 times per week, 1-hour ae sessions. all participants will continue their regular psychiatric and medical care. assessments of neurocognitive and daily functioning abilities, along with symptom severity, and physiological and behavioral measures of aerobic fitness will be completed before and after the 12-week program.

Eligibility criteria:
inclusion criteria: * males and females between ages 18-55. * have capacity to give informed consent. * english speaking. * have a dsm-iv diagnosis of schizophrenia. * taking antipsychotic medication for at least 8 weeks and on current doses for 4 weeks, and/or injectable depot antipsychotics with no change in last 3 months. * medically cleared to exercise. exclusion criteria: * lacks capacity to give informed consent. * have used street drugs within the past 4 weeks. * have history of of hypertension of cardiac conditions. * have history of active suicidal ideation or serious self-destructive behavior. * have history of violence or aggressive behavior. * have history of neurological or medical conditions known to seriously affect the brain. * pregnant or nursing. * completing more than 2 hours of moderate or higher levels of aerobic exercise per week. * participation in a study of cognition during the previous 2 months.

Keywords: schizophrenia cognition aerobic exercise